Hansa Medical proposes a directed share issue

0
Rate this post

The board of supervisors of Hansa Medical AB (publ) (” Hansa Medical” or the “Firm”) proposes a directed share concern of about SEK 185 million.

The registration cost for the concern is suggested to be SEK 70 per share.

The issue is guided to selected worldwide specialist financiers including HBM Healthcare Investments, Sectoral Asset Management, Sphera Funds Administration as well as Aescap, in addition to Swedish institutional and also strategic financiers including Carnegie Asset Monitoring,AFA Insurance Policy, KK-stiftelsen, Thomas Olausson and Unionen.

Investors standing for approximately 45 percent of the shares and also votes of Hansa Medical have undertaken to enact favour of the issue at the extraordinary general conference.

The board of directors has today introduced a notification for an extraordinary general meeting to solve on the share issue (for full information, see separate news release with notification for a remarkable conference).

NOT FOR CIRCULATION OR PUBLIC RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PROCEDURES WOULD BE IN VIOLATION OF APPLICABLE LAWS. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY DEAL, TO BUY OR SUBSCRIBE FOR ANY STOCKS IN HANSA MEDICAL IN ANY JURISDICTION.

Background and also reasons

In order to safeguard ongoing value creation for the Company of its projects, the board of supervisors suggests a guided concern of new shares. The problem earnings will mostly be bought the development of the drug candidate IdeS up to an application for market permission of IdeS in kidney hair transplant. The issue also allows the Firm to protect a broadened investor base with an increase in global and also Swedish institutional investors, which supplements the Business’s present solid shareholder base. All in all, the issue enables Hansa Medical to remain to turn into a pharmaceutical firm with exclusive items on the marketplace.

” The suggested directed concern is expected to protect the funds essential to develop our lead candidate IdeS as much as the filing for advertising and marketing permission of IdeS in treatment of kidney hair transplant”, claims Göran Arvidson, Chief Executive Officer of Hansa Medical.

” Our money placement, consisting of existing cash and also cash money equivalents, will also enable us to explore the safety and security and efficacy of IdeS via several Stage II scientific tests in a variety of prioritized indicators. These consist of the major autoimmune illness thrombotic thrombocytopenic purpura (TTP), anti-GBM illness as well as Guillain-Barré syndrome (GBS), as well as the transplant indicators antibody-mediated being rejected (AMR) article kidney transplantation as well as blood group inappropriate (ABOi) kidney transplantation. Our long-term vision is to develop IdeS as a treatment for fast and effective antibody inactivation in a large range of illness with substantial unmet clinical demand.”

The issue

The board of supervisors has solved to suggest the remarkable general conference to fix on a routed share concern of not more than 2,642,857 shares. The membership rate for the problem corresponds to SEK 70 per share, which, in overall, will supply the Company with roughly SEK 185 million before problem expenses. The membership cost for the concern has been determined through a so-called private placement treatment. The directed issue will be totally subscribed by a number of selected international expert financiers including HBM Health care Investments, Sectoral Possession Management, Sphera Finances Administration and Aescap, along with Swedish institutional and calculated financiers consisting of Carnegie Property Monitoring, AFA Insurance, KK-stiftelsen, Thomas Olausson and Unionen, in accordance with different agreements.

Shareholders representing approximately 45 percent of the shares as well as enact Hansa Medical, including Nexttobe AB, Gladiator and also Farstorps Gård AB, have actually embarked on to enact favour of the concern at the amazing basic conference.

The factors for the deviation from the investors’ pre-emption legal rights are that the Business shall, in a prompt way, be able to secure the Company’s funding demand for the operations, in addition to widen the ownership structure of the Business with calculated and institutional capitalists, which is additionally sustained by the Company’s biggest investors, who are not participating in the issue. Through the problem, the share funding will certainly boost with SEK 2,642,857 to SEK 35,054,860, which involves a dilution effect of roughly 8 per cent of both the number of shares and votes.

The extraordinary general conference will certainly be held on 21 November 2016 at the Firm’s workplaces on Scheelevägen 22 in Lund.

Advisors

Hansa Medical has, about the purchase, engaged Zonda Allies as expert, Carnegie Financial investment Bank as monetary consultant and Advokatfirman Vinge as legal expert.

This info is such information that Hansa Medical abdominal muscle (publ) is required to make public pursuant to the EU Market Abuse Policy. The information was submitted for publication, through the agency of the get in touch with individual laid out over, at 8:30 am CEST on 20 October 2016.

LÄMNA ETT SVAR

Vänligen ange din kommentar!
Vänligen ange ditt namn här